PROXIMAGEN NEUROSCIENCE PLC ("Proximagen" or "the Company") Disclosure of Information Required by AIM
Rule 26 Proximagen Neuroscience plc (AIM: PRX), the drug discovery and development company focused on neurodegenerative diseases, is pleased to announce that its website is now compliant with Rule 26 of the AIM Rules for Companies. This information can be viewed within the investor relations section of the Company’s website at the following address: www.proximagen.com/rule26.shtml. For more information please contact:
|